Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019

被引:0
|
作者
Mohamed, Adham [1 ]
Shemanski, Shelby M. [1 ]
Saad, Mohamed O. [2 ]
Ploetz, Jeannette [1 ]
Haines, Michelle M. [1 ,3 ]
Schlachter, Andrew B. [1 ,3 ]
Hamarshi, Majdi S. [1 ,3 ]
机构
[1] St Lukes Hosp, 4401 Wornall Rd, Kansas City, MO 64111 USA
[2] Hamad Med Corp, Al Wakra Hosp, Doha, Qatar
[3] Univ Missouri, Sch Med, Kansas City, MO 64108 USA
关键词
COVID-19; thromboprophylaxis; anticoagulation; venous thromboembolism; bleeding; DOSE THROMBOPROPHYLAXIS; VENOUS THROMBOEMBOLISM; COVID-19; COAGULOPATHY; HEMORRHAGE;
D O I
10.1177/10760296221116350
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare Anti-Xa directed thromboprophylaxis using low molecular weight heparin (LMWH) (anti-Xa peak goal 0.2-0.5 IU/mL) to alternative anticoagulation strategies in critically ill COVID-19 patients. Methods: This was a retrospective, multicenter, single health-system study. Primary outcomes were thromboembolic events and clinically important bleeding events. Secondary outcomes included dosing comparisons between LMWH cohorts. Main Results: A total of 695 patients were included. No differences were found in the incidence of thrombotic events with any of the dosing strategies. The incidence of major bleeding was significantly higher in the standard dose thromboprophylaxis, intermediate dose subcutaneous heparin (SQH), and therapeutic anticoagulation cohorts. Forty-nine percent of patients within the anti-Xa directed group had their first anti-Xa peak at goal, while 43% were above goal. Patients who had levels above goal had dose modifications made, therefore anti-Xa directed LMWH resulted in significantly lower total daily doses compared to intermediate dose LMWH. Conclusions: Anti-Xa directed LMWH dosing provided comparable thromboprophylaxis with lower total daily doses of LMWH in critically ill COVID-19 patients. Further randomized controlled trials are needed to confirm our findings.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
    Mohamed, Adham
    Shemanski, Shelby M.
    Saad, Mohamed O.
    Ploetz, Jeannette
    Haines, Michelle M.
    Schlachter, Andrew B.
    Hamarshi, Majdi S.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [2] Anti-Xa levels in critically ill patients receiving dalteparin for thromboprophylaxis.
    McDonald, E
    Dale, C
    Pleasance, S
    McNeill, A
    Harvey, J
    Wynne, C
    Duffett, M
    Provost, L
    Rioux, A
    LaRouche, G
    Davidson, C
    Watpool, I
    McCardle, T
    Foxall, J
    Bouwers, K
    Lewis, MJ
    Zytaruk, N
    Griffith, L
    Crowther, M
    Cook, D
    [J]. BLOOD, 2004, 104 (11) : 105B - 105B
  • [3] THROMBOPROPHYLAXIS USING ANTI-XA LEVELS IN OBESE CRITICALLY ILL PATIENTS: A RETROSPECTIVE STUDY
    Cagliani, Joaquin
    Nio, Kosuma
    Wu, Wenchen
    Smith, Candace
    Park, Jayoung
    Rik, Horacio
    Nicastro, Jeffrey
    Barrera, Rafael
    [J]. CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [4] No effect of norepinephrine dose on anti-Xa activity in critically ill patients
    Meenks, Sjoerd D.
    Foudraine, Norbert A.
    Broen, Kelly
    le Noble, Jos L. M. L.
    Janssen, Paddy K. C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (04) : 223 - 229
  • [5] Optimizing the Risk-Benefit Balance of Thromboprophylaxis in Critically Ill Patients With Coronavirus Disease 2019
    Piagnerelli, Michael
    Cauchie, Philippe
    Wautrecht, Jean-Claude
    [J]. CRITICAL CARE MEDICINE, 2020, 48 (10) : E988 - E989
  • [6] Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients
    Taccone, Fabio Silvio
    Gevenois, Pierre Alain
    Peluso, Lorenzo
    Pletchette, Zoe
    Lheureux, Olivier
    Brasseur, Alexandre
    Garufi, Alessandra
    Talamonti, Marta
    Motte, Serge
    Nobile, Leda
    Grimaldi, David
    Creteur, Jacques
    Vincent, Jean-Louis
    [J]. CRITICAL CARE MEDICINE, 2020, 48 (11) : E1087 - E1090
  • [7] COMPARISON OF ANTI-XA LEVELS BETWEEN OBESE AND NON-OBESE CRITICALLY ILL PATIENTS RECEIVING UNFRACTIONATED HEPARIN THROMBOPROPHYLAXIS
    Blum, Mark
    Park, Jayoung
    Wu, Wenchen
    Belchikov, Yuly
    Smith, Candace
    Barrera, Rafael
    [J]. CRITICAL CARE MEDICINE, 2012, 40 (12) : U254 - U254
  • [8] Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients
    Vincent, Philippe D.
    Albert, Martin
    Champagne, Marie-Christine
    Zikos, Theodora
    Boulanger, Isabelle
    Blais, Lucie
    Williamson, David R.
    [J]. JOURNAL OF CRITICAL CARE, 2011, 26 (04) : 347 - 351
  • [9] Optimizing the Risk-Benefit Balance of Thromboprophylaxis in Critically Ill Patients With Coronavirus Disease 2019 Reply
    Iba, Toshiaki
    Levy, Jerrold H.
    Levi, Marcel
    Connors, Jean Marie
    Thachil, Jecko
    [J]. CRITICAL CARE MEDICINE, 2020, 48 (10) : E989 - E990
  • [10] Carboxyhemoglobinemia in Critically Ill Coronavirus Disease 2019 Patients
    Faisal, Hina
    Ali, Syeda T.
    Xu, Jiaqiong
    Nisar, Tariq
    Sabawi, Mahmoud
    Salazar, Eric
    Masud, Faisal N.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)